As a portal company that establishes connections between universities and companies and between companies and companies, we cover a wide range of fields, from iPS cell culture to the use of associated instruments to promote the commercialization of iPS technologies. We provide new platforms to contribute effectively to development in the fields of drug discovery and regenerative medicine.
Upon obtaining a transfer of all businesses other than the patent for iPS Academia Japan, Inc., iPS Portal, Inc. started the operation from September 2014.
Our company was the first in Japan to be certified as a National Strategic Special Zone operator for “Business of manufacture of specified research tools from blood” after the relaxation of regulations of the Blood Law in February 2016. We are now the only company in Japan that can produce diseased iPS cells established from patient blood samples for business purposes.
We signed a partnership agreement with RIKEN BioResource Center, Institute of Physical and Chemical Research (RIKEN BRC) for mutual utilization of diseased iPS cells and other samples in April 2017.
iPS technologies have a wide range of applications and contribute to many technologies, products, and companies related to drug discovery research and regenerative medicine.
Experienced researchers on the iPS Portal provide technologies, information, and services to fit the needs and timelines of companies that operate in the fields of drug discovery and regenerative medicine. By improving the efficiency of research and development, we help such companies to achieve success.
As a National Strategic Special Zone operator, we offer a diseased and polymorphous iPS cell panel as a new platform for drug discovery with iPS technologies produced from iPS cells derived from the blood samples of Japanese patients, which places less burden on patients.
|Company Name||iPS Portal, Inc|
|Founded||July 31, 2014|
|Address||Creation Core Kyoto Mikuruma, 448-5 Kajii-cho, Imadegawa-Sagaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0841, Japan|
|Capital||1.5646 billion yen (capital stock of 799,600,000 yen and capital reserve of 765,000,000 yen)|
|Number of employees||24 (as of the end of June 2017)|
|Managing Directors||CEO Shosaku Murayama
COO Masakazu Kobayashi
|Directors||Yoshio Yamaoka (Kyoto University, Honorary Professor)
Kozo Miseki (Shimadzu Corporation)
|Auditor||Yoshito Fujikawa (Lawyer and Patent Attorney, Yodoyabashi & Yamagami Legal Professional Corporation)|
|Scientific Advisory Board:||Junya Toguchida (Deputy Director, Center for iPS Cell Research and Application, Kyoto University)
Kenji Osafune (Professor, Center for iPS Cell Research and Application, Kyoto University)
Shimon Sakaguchi (Honorary Professor, Osaka University, and Honorary Professor, Kyoto University)
|Management Advisory Board||Motoshige Ito (Honorary Professor, The University of Tokyo, and Professor, Gakushuin University)
Richard C. Koo (Chief Researcher, Center for Strategic Management & Innovation, Nomura Research Institute)
|Consultants||Hideo Saji (Honorary Professor, Kyoto University)
Masahiro Kinooka (Professor, Graduate School of Engineering Osaka University)
Tadahisa Kagimoto (President and CEO, Healios K.K.)
Eisai Co., Ltd.
Ajinomoto Co., Inc
Shin Nippon Biomedical Laboratories, Ltd
SCREEN Holdings Co., Ltd.
TOHO HOLDINGS CO., LTD.
Toyo Seikan Group Holdings, Ltd.
Chugai Pharmaceutical Co., Ltd.
Daiichi Jitsugyo Co., Ltd.
iPS Academia Japan, Inc.
Sumitomo Mitsui Banking Corporation
SMBC Venture Capital Co., Ltd.
Daiwa Securities Group Inc.
Diseased iPS Cell Panel
Depending on the disease, the appropriate disease model may be unavailable and differences in the efficacy/toxicity of drugs can be caused by a variety of gene polymorphisms. The solution to these challenges is the diseased/polymorphous iPS cell panel, which is produced from iPS cells derived from multiple patients and enables the reproduction of disease conditions and differences between gene polymorphisms. In collaboration with RIKEN BRC, we provide a diseased iPS cell panel as a novel and more value-added platform for drug discovery through the mutual complement and utilization of the diseased iPS cells held by RIKEN BRC and the diseased iPS cells produced by our company under the National Strategic Special Zone business.
“Open Lab” for Drug Discovery Assays
Open Lab for Drug Discovery Assays is designed to provide a space for the feasibility studies of drug discovery assays by using diseased iPS cell panels. Experiments using diseased iPS cells or differentiated cells can be conducted without cumbersome procedures. Analytical instruments, such as FACS systems, image analyzers (HCS, HTS), electrophysiological measurement devices (MEA), mass spectrometers (LC-MS), and digital PCR systems are installed in a single space. Therefore, new assay systems can be built up efficiently with combinations of these instruments.
Contract Services for Culture and Differentiation Induction of iPS Cells
We assist in the improvement of the efficiency of research and development by lessening the cumbersome maintenance culture of iPS cells or the time-consuming preliminary investigation of methods of differentiation induction. The available services include culture growth maintenance, new iPS cells establishment, modification, sorting, analysis, and the differentiation induction of iPS cell stock
Contract Service for Evaluation of Instruments and Reagents Consulting Service
From the perspective of specialists handling iPS cells, we conduct evaluations to add value, to fit your objectives or stages of development, or to maximize the potential of products and technologies that you develop. A long-term consulting service for sales promotion is also available.
We provide training programs to suit the needs of a range of customers, from those with no cell culture experience to those with iPS cell culture experience. The training programs can be customized to meet your needs.
- iPS cell culture experience training (training for business/development planning personnel and training for business managers)
- iPS cell culture technician training (training for new employees/technicians to improve proficiency)
- Training in applications of diseased iPS cells
iPS Cells Business Council
Targeting companies with an interest in business launches and business development in iPS-related fields, we conduct regular meetings to exchange information with a focus on the themes surrounding commercialization.
iPS Cells Utilization Guide on Website
This is a free website run by our company for companies and researchers seeking a wide range of information related to iPS cells.
This website introduces videos of procedures used in the processes of establishment, maintenance culture, testing of iPS cells, a variety of protocols for differentiation induction that have been validated in reproductive experiments, and recommendations for instruments, reagents, and tools.
|By Train||Approximately 7 minutes by walk from Keihan-Line, “Demachi Yanagi” Station|
|By Bus||Approximately 40 minutes from JR Kyoto Station to “Kawaramachi Imadegawa”, and approximately two minutes’ walk from the bus stop|
|By Taxi||Approximately 25 minutes from JR Kyoto Station, at a cost of approximately 1,800 yen|